Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden

Harnessing the immune system by checkpoint blockade has greatly expanded the therapeutic options for advanced cancer. Since the efficacy of immunotherapies is influenced by the molecular make-up of the tumor and its crosstalk with the immune system, comprehensive analysis of genetic and immunologic...

Full description

Bibliographic Details
Main Authors:	Jan Budczies, Anja Seidel, Petros Christopoulos, Volker Endris, Matthias Kloor, Balázs Győrffy, Barbara Seliger, Peter Schirmacher, Albrecht Stenzinger, Carsten Denkert
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2018-12-01
Series:	OncoImmunology
Subjects:	immuno-oncology immune checkpoints pd-l1 tumor mutational burden mutational signatures
Online Access:	http://dx.doi.org/10.1080/2162402X.2018.1526613

Similar Items

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
by: Timothy V. Pham, et al.
Published: (2020-08-01)

Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer
by: Hao Chen, et al.
Published: (2020-01-01)

Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma
by: Rui Zhang, et al.
Published: (2021-02-01)

Determining mutational burden and signature using RNA-seq from tumor-only samples
by: Erik Jessen, et al.
Published: (2021-03-01)

Beyond the Variants: Mutational Patterns in Next-Generation Sequencing Data for Cancer Precision Medicine
by: Megan Parilla, et al.
Published: (2020-05-01)

Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma
by: Wang H, et al.
Published: (2021-05-01)

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
by: Hao Chen, et al.
Published: (2019-05-01)

Corrigendum: Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
by: Hao Chen, et al.
Published: (2019-07-01)

Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer
by: Stefanie Schatz, et al.
Published: (2020-06-01)

Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival
by: Yanmei Gao, et al.
Published: (2020-10-01)

miRNA-Based Signature Associated With Tumor Mutational Burden in Colon Adenocarcinoma
by: Weijie Xue, et al.
Published: (2021-06-01)

A Prognostic Model of 15 Immune-Related Gene Pairs Associated With Tumor Mutation Burden for Hepatocellular Carcinoma
by: Junyu Huo, et al.
Published: (2020-11-01)

Generating realistic null hypothesis of cancer mutational landscapes using SigProfilerSimulator
by: Erik N. Bergstrom, et al.
Published: (2020-10-01)

SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events
by: Erik N. Bergstrom, et al.
Published: (2019-08-01)

decompTumor2Sig: identification of mutational signatures active in individual tumors
by: Sandra Krüger, et al.
Published: (2019-04-01)

Predictive Value of Tumor Mutation Burden in Immunotherapy for Lung Cancer
by: Huanlan SA, et al.
Published: (2019-06-01)

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
by: Si-Cong Ma, et al.
Published: (2021-06-01)

MutationalPatterns: comprehensive genome-wide analysis of mutational processes
by: Francis Blokzijl, et al.
Published: (2018-04-01)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
by: Yongfeng Wu, et al.
Published: (2019-11-01)

Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
by: Sridhar Nimmagadda
Published: (2020-10-01)

CoMutPlotter: a web tool for visual summary of mutations in cancer cohorts
by: Po-Jung Huang, et al.
Published: (2019-07-01)

Secondary Somatic Mutations in G-Protein-Related Pathways and Mutation Signatures in Uveal Melanoma
by: Francesca Piaggio, et al.
Published: (2019-10-01)

SigsPack, a package for cancer mutational signatures
by: Franziska Schumann, et al.
Published: (2019-09-01)

Genomic and immunologic correlates of LAG-3 expression in cancer
by: Anshuman Panda, et al.
Published: (2020-01-01)

Hypoxia increases mutational load of breast cancer cells through frameshift mutations
by: Goutham Hassan Venkatesh, et al.
Published: (2020-01-01)

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
by: Yu Chen, et al.
Published: (2020-09-01)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
by: Yang W, et al.
Published: (2020-09-01)

Correlate tumor mutation burden with immune signatures in human cancers
by: Xiaosheng Wang, et al.
Published: (2019-01-01)

Impact of cancer mutational signatures on transcription factor motifs in the human genome
by: Calvin Wing Yiu Chan, et al.
Published: (2019-05-01)

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
by: Yongfeng Wu, et al.
Published: (2020-04-01)

Repeat-induced point mutation in Neurospora crassa causes the highest known mutation rate and mutational burden of any cellular life
by: Long Wang, et al.
Published: (2020-06-01)

Identification and validation of a miRNA-related expression signature for tumor mutational burden in colorectal cancer
by: Lijun Xu, et al.
Published: (2021-02-01)

Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers
by: Zhe-Yu Hu, et al.
Published: (2020-08-01)

NIMBus: a negative binomial regression based Integrative Method for mutation Burden Analysis
by: Jing Zhang, et al.
Published: (2020-10-01)

Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer
by: Bahman Afsari, et al.
Published: (2021-01-01)

Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma
by: Jia Li, et al.
Published: (2021-09-01)

Germline and somatic variations influence the somatic mutational signatures of esophageal squamous cell carcinomas in a Chinese population
by: Jintao Guo, et al.
Published: (2018-07-01)

High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas
by: Ping Mei, et al.
Published: (2020-05-01)

Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients
by: Gang Guo, et al.
Published: (2021-04-01)

Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers
by: Peng-Chan Lin, et al.
Published: (2021-08-01)

Cannot write session to /tmp/vufind_sessions/sess_d7ihkdeg8faahsbpqncc7fe41d